Private placement of shares in A3P Biomedical AB (SE) – SEK 400 million

Carnegie acted as sole financial adviser in A3P Biomedical’s private placement of shares of SEK 400 million. The purpose of the share issue is to finance the Company’s growth strategy and accelerate the commercialization of Stockholm3®, as well as broaden the investor base. The company’s lead product, Stockholm3®, is a blood test for early detection of aggressive prostate cancer. Stockholm3® combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer. A3P Biomedical’s mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics.
May 2022.